Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Hodgkin Disease 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 32Vincristine 22blinatumomab 20Methotrexate 20Specimen Handling 19Prednisone 19Cytarabine 17merphos 16prednylidene 15deltacortene 15Biopsy 15Mercaptopurine 14Doxorubicin 14Dexamethasone 14N,N-dicyclohexyl-isoborneol-10-sulfonamide 13pegaspargase 12azathiopurine 12Rituximab 12Etoposide 12dexamethasone acetate 11dexamethasone 21-phosphate 11auricularum 11Spinal Puncture 11Calcium Dobesilate 11Asparaginase 11Leucovorin 10fludarabine 9Magnetic Resonance Spectroscopy 9Inotuzumab Ozogamicin 9Daunorubicin 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Burkitt Lymphoma × tafasitamab × 90 days × Clear all
NCT05453500 2026-05-11

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

University of Washington

Phase 2 Active not recruiting
32 enrolled
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡